FDA concerns hit Replimune stock
Analysis based on 9 articles · First reported Jul 30, 2026 · Last updated Aug 07, 2026
The FDA's concerns triggered a sharp decline in Replimune's stock price, reflecting heightened regulatory and clinical risk for its lead product candidate. The investigation by Pomerantz LLP adds legal overhang, potentially further pressuring investor sentiment and the company's market valuation.
On July 28, 2026, the United States — Food and Drug Administration published briefing documents expressing concerns about the data package submitted by Replimune Group to support accelerated approval of its drug RP1 (vusolimogene oderparepvec) in combination with Bristol Myers Squibb's PD-1 inhibitor Opdivo for adults with unresectable advanced cutaneous melanoma who progress after PD-1-blocking antibody therapy. The FDA stated that the response assessment used in the Phase 1/2 IGNYTE study confounds interpretation of the reported efficacy results and limits the agency's ability to verify the reported results. Following this news, Replimune's stock price fell $3.28 per share, or 38.01%, to close at $5.35 per share on July 28, 2026. Subsequently, Pomerantz LLP announced it is investigating claims on behalf of Replimune investors concerning whether the company and certain officers and/or directors engaged in securities fraud or other unlawful business practices.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard